SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocketman who wrote (6100)12/8/1998 10:46:00 AM
From: Vector1  Read Replies (1) of 9719
 
Todays news. This is promising. Lets add anoather 1000 shares at 12
MINNEAPOLIS (Dow Jones)--MGI Pharma Inc. (MOGN) added 16 patients to the
exploratory prostate cancer Phase II study of its MGI 114 drug.
In a press release Tuesday, the pharmaceutical company said the anticancer
drug's trial was expanded after it observed the minimum response criteria for
trial expansion.
Expansion required that at least two patients show a greater than 50% drop
in prostate-specific antigen levels following treatment with MGI 114.
The drug's current study was initiated as an exploratory Phase II trial in
July. It was designed to treat at least 14 hormone-refractory prostate cancer
patients.
(
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News